We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GSK PLC on Wednesday said its meningitis vaccine, Menveo, has received approval from the European Commission in a new ...
GSK PLC 27 November 2024 Issued: 27 November 2024, London UK GSK's fully liquid Menveo meningococcal vaccine approved by European Commission · New fully liquid presentation means...
GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenre ...
GSK PLC 25 November 2024 Issued: 25 November 2024, London UK Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma · Regulatory...
GSK PLC said on Friday that Japan's Ministry of Health, Labour & Welfare has approved the expansion of its Arexvy re ...
GSK PLC 22 November 2024 Issued: 22 November 2024, London UK Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan · First RSV vaccine approved...
GSK PLC 19 November 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr Hal Barron b) Position/status...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 40.5 | 3.11538461538 | 1300 | 1351.5 | 1300 | 7048206 | 1337.66995359 | DE |
4 | -56 | -4.01002506266 | 1396.5 | 1435 | 1282.5 | 9530512 | 1351.69602845 | DE |
12 | -327.5 | -19.6342925659 | 1668 | 1678 | 1282.5 | 8516960 | 1457.82976176 | DE |
26 | -436 | -24.5426400225 | 1776.5 | 1776.5 | 1282.5 | 7997173 | 1523.09232529 | DE |
52 | -67.7 | -4.80755574492 | 1408.2 | 1820 | 1282.5 | 7871403 | 1566.53647517 | DE |
156 | -175.1 | -11.5531802586 | 1515.6 | 1824.4 | 1282.5 | 8641759 | 1531.28817569 | DE |
260 | -410.7 | -23.4524897213 | 1751.2 | 1857 | 1190.8 | 8812214 | 1512.92808636 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions